European Journal of Cancer
Volume 37, Issue 18 , Pages 2302-2309 , December 2001

Recent advances in the management of colorectal cancer

  • E Van Cutsem

      Affiliations

    • Department of Internal Medicine, University Hospital Gosthuisberg, Herestraat 49, BE-3000 Leuven, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32-16-344225; fax: +32-16-344419
    • ,
  • M Dicato

      Affiliations

    • Luxembourg Medical Centre, Luxembourg
    • ,
  • J Wils

      Affiliations

    • Laurentius Hospital, Roermond, The Netherlands

Received 6 February 2001 ,Revised 12 July 2001 ,Accepted 12 July 2001.

References 

  1. Willert K, Nusse R. β-catenin (a key mediator of Wnt signaling). Curr. Opin. Genet. Dev. 1998;8:95–102
  2. Su LK, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. Science. 1993;262:1734–1737
  3. Smits R, Kielman MF, Breukel C, et al.  Apc 1638T (a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorgenesis and development). Genes Devel. 1999;13:1309–1321
  4. Nugent KP, Farmer KC, Spigelman AD, et al.  Randomized, controlled trial of the effect of sundilac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg. 1993;80:1618–1619
  5. Eberhart CE, Coffey RJ, Radhika A, et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183–1188
  6. Oshima M, Dinchuk JE, Kargman SL, et al.  Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996;87:803–809
  7. Steinbach G, Lynch PM, Phillips RKS, et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000;342:1946–1952
  8. Rex DK, Vining D, Kopecky KK. An initial experience with screening for colon polyps using spiral CT with and without CT colography (virtual colonoscopy). Gastrointest. Endosc. 1999;50:437–440
  9. The Swedish Rectal Cancer Trial . Improved survival with preoperative radiotherapy in resectable cancer. N. Engl. J. Med. 1997;336:980–987
  10. Pahlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann. Surg. 1990;211:187–195
  11. Gastrointestinal Tumour Study Group—GITSG 7175. Prolongation of disease-free interval in surgically treated rectal carcinoma . N. Engl. J. Med. 1985;312:1464–1472
  12. Krook JE, Moertel CG, Gundersen LL, et al.  Effective surgical adjuvant therapy for high risk rectal cancer. New Engl. J. Med. 1991;324:709–715
  13. Tveit KM, Guldvog I, Trondsen E, et al.  Randomised controlled trial of post operative radiotherapy and short term time scheduled 5-fluorouracil against surgery alone in the treatment of Duke's B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group. Br. J. Surg. 1997;84:1130–1135
  14. O'Connell MJ, Martensen JA, Wieand HS, et al.  Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N. Engl. J. Med. 1994;331:502–507
  15. Wolmark N, Wieand HS, Hyams DM, et al.  Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum. National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J. Natl. Cancer Inst. 2000;92:388–396
  16. Kapiteijn E, Kranenbarg EK, Steup WH, et al.  Total mesorectal excision (TME) with or without preoperative radiotherapy in the treatment of primary rectal cancer. Prospective randomised trial with standard operative and histopathological techniques. Dutch ColoRectal Cancer Group. Eur. J. Surg. 1999;165:410–420
  17. Francois Y, Nemoz CJ, Baulieux J, et al.  Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer (the Lyons R90-01 randomized trial). J. Clin. Oncol. 1999;17:2396–2402
  18. Cocconi G, Cunningham D, Van Cutsem E, et al.  Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J. Clin. Oncol. 1998;16:2943–2952
  19. Cunningham D, Zalcberg JR, Rath U, et al.  ‘Tomudex’ (ZD1694) (results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The ‘Tomudex’ Colorectal Cancer Study Group). Eur. J. Cancer. 1995;31A:1945–1954
  20. Comella P, De Vita F, Mancarella S, et al.  Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma (a Southern Italy Cooperative Oncology Group phase II-III randomized trial). Ann. Oncol. 2000;11:1323–1333
  21. Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, et al.  Clinical activity and benefit of Irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-Fluorouracil (5-FU). Eur. J. Cancer. 1999;35:54–59
  22. Cunningham D, Pyrhönen S, James RD, et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1413–1418
  23. Rougier P, Van Cutsem E, Bajetta E, et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352:1407–1412
  24. Douillard JY, Cunningham D, Roth AD, et al.  Irinotecan combined with fluorouracil compared to fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041–1047
  25. Saltz LB, Cox JV, Blanke C, et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2000;343:905–915
  26. Armand J-P, Boige V, Raymond E, et al.  Oxaliplatin in colorectal cancer (an overview). Semin. Oncol. 2000;27(Suppl. 10):96–104
  27. De Gramont A, Figer A, Seymour M, et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000;18:2938–2947
  28. Falcone A, Masi G, Pfanner E, et al.  Phase I-II study of Irinotecan (CPT-11), Oxaliplatin (LOHP), Leucovorin (LV) and 5-Fluorouracil (5-FU) 48 hours continuous infusion (C.I.) in metastatic colorectal cancer patients. Proc. Am. Soc. Clin. Oncol. 2000;19:297a
  29. Calvo E, Gonzalez-Cao M, Cortes J, et al.  Combined irinotecan, oxaliplatin, 5-FU in patients (PTS) with metastatic colorectal cancer (MCC). Proc. Am. Soc. Clin. Oncol. 2000;19:259a
  30. Lepille D, Douillard JY, Marre A, et al.  Essai randomisé de phase II évaluant 3 associations en traitement de seconde ligne du cancer colorectal métastatique: LV5FU2+CPT11 vs LV5FU2+LOHP vs LOHP+CPT11. Gastroenterol. Clin. Biol. 2000;24:183a
  31. Tournigand C, Louvet C, Quinaux E, et al.  Folfiri followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (final results of a phase III study). Proc. Am. Soc. Clin. Oncol. 2001;20:494a
  32. Miwa M, Ura M, Nishida M, et al.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer. 1998;34:1274–1281
  33. Van Cutsem E, Findlay M, Osterwalder B, et al.  Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer (results of a randomized phase II study). J. Clin. Oncol. 2000;18:1337–1345
  34. Schüller J, Cassidy J, Dumont E, et al.  Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. 2000;45:291–297
  35. Baccanari DP, Davis ST, Knick VC, et al.  5-Ethynyluracil (776C85) (a potent modulator of the pharmacokinetics and antitumour efficacy of 5-fluorouracil). Proc. Natl. Acad. Sci. USA. 1993;90:11064–11068
  36. Tuchman M, Ramnaraine ML, O'Dea RF, et al.  Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil and thymine by rat liver dihydropyrimidine dehydrogenase. Cancer Res. 1985;45:5553–5556
  37. Ahmed FY, Johnston SJ, Cassidy J, et al.  Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumours. J. Clin. Oncol. 1999;17:2439–2445
  38. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol, in press.
  39. Hoff PM, Ansari R, Batist G, et al.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer (results of a randomized phase III study). J. Clin. Oncol. 2001;19:2282–2292
  40. Pazdur R, Douillard JY, Skillings JR, et al.  Multicenter phase III study of 5-fluorouracil (5-FU) or UFT™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 1999;18:263a
  41. Carmichael J, Popiela T, Radstone D, et al.  Randomized comparative study of Orzel® (oral uracil/tegafur) (UFT™) plus LV (LV) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 1999;18:264a
  42. Van Cutsem E, Sorensen J, Cassidy J, et al.  International phase III study of oral Eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC). Proc. Am. Soc. Clin. Oncol. 2001;20:131a
  43. Schleucher N, Tewes M, Achterrath W, et al.  Extended phase I study of capecitabine in combination with a weekly schedule of irinotecan as first line chemotherapy in metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 2001;20:561a
  44. Evans J, Tabernero J, Cassidy J, et al. Safety profile and preliminary efficacy of capecitabine (Xeloda®) in combination with oxaliplatin in patients with advanced or metastatic solid tumours: results from a phase I study. Ann Oncol 2000; 11 (Suppl. 4), 51 (abstr 222).
  45. Bollag G, McCormick F. Regulators and effectors of ras proteins. Annu. Rev. Cell Dev. Biol. 1991;7:601–632
  46. Lui M, Bryant MS, Chen J, et al.  Antitumor activity of SCH66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. 1998;58:4947–4956
  47. Skrzat S, Angibaud P, Venet M, et al.  R115777, a novel imidazole farnesyl transferase inhibitor (FTI) with potent oral antitumor activity. Proc. Am. Soc. Cancer Res. 1998;39:2170a
  48. Takahashi Y, Kitadai Y, Bucana CD, et al.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55:3964–3968
  49. Brown LF, Berse B, Jackman RW, et al.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptor in adenocarcinomas of the gastrointestinal tract. Cancer Res. 1993;53:4727–4735
  50. Cardiello F, Bianco R, Damiano V, et al.  Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. 2000;6:3739–3747
  51. Kanai T, Konno H, Tanaka T, et al.  Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int. J. Cancer. 1998;77:933–936
  52. Ellis L, Takahashi Y, Liu W, et al.  Vascular endothelial growth factor in human colon cancer (biology and therapeutic implications). Oncologist. 2000;5:11–15
  53. Saltz L RubinM, Hochster H, et al.  Cetuximal (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer that expresses Epidermal Growth Factor Receptor. Proc. Am. Soc. Clin. Oncol. 2001;20:7a
  54. Peters GJ, Van der Wilt CL, Van Groeningen CJ, et al.  Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J. Clin. Oncol. 1994;12:2035–2042
  55. Leichman CG, Danenberg PV, Tan M, et al.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 1997;15:3223–3229
  56. Yamachika T, Nakanishi H, Inada KL, et al.  A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer (Phila.). 1998;82:70–77
  57. Lenz HJ, Hayashi K, Salonga D, et al.  p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer (an analysis of response and survival). Clin Cancer Res. 1998;4:1243–1250
  58. Leggett B, Young J, Buttenshaw R, et al.  Colorectal carcinomas show frequent allelic loss on the long arm of chromosome 17 with evidence for a specific target region. Br. J. Cancer. 1995;71:1070–1073
  59. Lanza G, Matteuzzi M, Gafa R, et al.  Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int. J. Cancer. 1998;79:390–395
  60. Elsaleh H, Joseph DJ, Lacopetta B. Microsatellite instability is a strong molecular predictive marker for sensitivity to adjuvant chemotherapy in Dukes’ C colorectal carcinoma. Proc. Am. Soc. Clin. Oncol. 2000;19:238a

PII: S0959-8049(01)00249-0

doi: 10.1016/S0959-8049(01)00249-0

European Journal of Cancer
Volume 37, Issue 18 , Pages 2302-2309 , December 2001

Article Tools